Latest Conference Articles

In older patients with comorbid classical Hodgkin lymphoma who are deemed unfit for combination chemotherapy, treatment with the antibody dug conjugate brentuximab vedotin appeared tolerable and achieved high response rates that were durable in some patients, according to results from the phase 2 SGN35-015 study.

Robert Zeiser, MD, discusses the findings from the phase 3 REACH3 clinical trial of ruxolitinib as treatment of patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.

A study presented during the 2020 ASH Annual Meeting has suggested that certain driver mutations for myeloproliferative neoplasms can be traced back to when they were acquired as early as in utero.

A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.

Treatment with asciminib led to an almost doubling of the major molecular response rate compared with bosutinib at 24 weeks in patients with chronic-phase chronic myeloid leukemia.

The combination of pevonedistat and azacitidine demonstrated encouraging efficacy and longer event-free survival compared with azacitidine alone in patients with higher-risk myelodysplastic syndromes.

Results for the phase 3 ANDROMEDA study showed an improvement in hematologic complete response rates with the combination of daratumumab plus bortezomib, cyclophosphamide, and dexamethasone compared with VCd alone in patients with newly diagnosed amyloid light-chain amyloidosis.

Chimeric antigen receptor T-cell therapy with lisocabtagene maraleucel led to rapid and durable responses in patients with high-risk relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

High response rates and robust survival outcomes among patients with chronic-phase chronic myeloid leukemia who failed prior treatment with a second-generation tyrosine kinase inhibitor were observed in 2 clinical trials of ponatinib,.

A 20-mg 3-times-weekly or twice-weekly dosing schedule of panobinostat combined with subcutaneous bortezomib plus dexamethasone induced durable responses as treatment of patients with relapsed or refractory multiple myeloma and demonstrated an acceptable safety profile in the phase 2 PANORAMA 3 study.

The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

Adult patients with acute lymphoblastic leukemia who have relapsed following hematopoietic cell transplantation have experienced considerably improved survival benefits over the past few years, which may be due to an increased use of immunotherapy.

Ixazomib in combination with lenalidomide plus dexamethasone achieved a clinically meaningful improvement of 13.5 months in the median progression-free survival as treatment of elderly patients with transplant-ineligible newly diagnosed multiple myeloma.

Luspatercept demonstrated clinical efficacy and a tolerable safety profile in patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who were enrolled in the MEDALIST trial.

The combination of daratumumab with lenalidomide, bortezomib, and dexamethasone followed by maintenance therapy with daratumumab and lenalidomide improved response rates and depth of response rates with statistically significance as treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

In the phase 3 UNITY-CLL study, ublituximab in combination with umbralisib demonstrated synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

Patients with relapsed or refractory non-Hodgkin lymphomas treated with glofitamab in the phase 1 NP30179 study, had a significant rate of complete responses.

Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.

In the phase 3 APOLLO study, patients with relapsed/refractory multiple myeloma who had received 1 or more prior line of therapy had a significantly reduced the risk of progression or death by 37% when treated with the combination of subcutaneous daratumumab to pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone.

The most important factor associated with poor survival among patients below 60 years of age with acute myeloid leukemia was self-reported black race in a SEER analysis.

Idecabtagene vicleucel demonstrated clinically meaningful improvements in the quality-of-life of triple-class exposed patients with relapsed/refractory multiple myeloma in the phase 2 KarMMA trial.

Promising antitumor activity, as well as an acceptable safety profile, continues to be demonstrated with odronextamab, a novel CD20xCD3 bispecific antibody, as treatment of patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

The novel oral cereblon E3 ligase modulator agent CC-92480 in combination with dexamethasone was found to be pharmacologically active with immunomodulatory activity at all doses as treatment of patients with relapsed/refractory multiple myeloma.

The precision Treg-engineered donor product Orca-T exhibited preventive potential for graft-versus-host disease in patients with high-risk hematologic malignancies who underwent hematopietic stem cell transplantation, with less immunosuppression compared with the standard of care.

Patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel experienced rapid and clinically meaningful improvements in health-related quality of life and trends suggested that HRQoL benefits may be greater as responses to therapy deepen over time.

Treatment with IGM-2323, a bispecific IgM antibody, resulted in tumor shrinkage in 9 of 14 patients with CD20-positive relapsed/refractory non-Hodgkin lymphoma in a phase 1 study.

In patients with acute myeloid leukemia and myelodysplastic syndrome, treatment with sabatolimab administered at 200 mg every 2 weeks and 800 mg every 4 weeks demonstrated similar pharmacokinetic activity, according to findings from a dose-selection and dose-response analysis presented during the 2020 American Society of Hematology Annual Meeting.

An overall response rate of 53% was observed with the first-of-its-kind FcRH5xCD3 bispecific antibody cevostamab along with manageable safety as treatment of patients with heavily pretreated patients with relapsed/refractory multiple myeloma who received active doses, according to results from a phase 1 dose-escalation study.

Encouraging response rates were observed in patients with relapsed or refractory multiple myeloma who were treated with off-the-shelf DuoBody IgG4 PAA binding antibody talquetamab. In addition, the agent showed a tolerable safety profile, according to early data from a phase 1 clinical trial.

Patients with relapsed or refractory multiple myeloma had deep and durable responses to the BCMA- and CD3-targeted bispecific monoclonal antibody REGN5458, early on in the course of treatment, according to findings from a first-in-human phase 1 study.